F	0	R	Μ	4	

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response. 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Thit of Type Response	(3)								1		
1. Name and Address o Jeong Tae Heum		2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RXHN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
9620 MEDICAL CH	(First) ENTER DRIVE		3. Date of Earliest Transaction (Month/Day/Year) 12/08/2005					er (specify below	v)		
(Street) ROCKVILLE, MD 20850			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	Execution Date, if			(A) or Disposed of (D) (Instr. 3, 4 and 5)		f (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form:	7. Nature of Indirect Beneficial
			(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1474 (9-02) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of				4.		5. Number of		6. Date Exercisable and		7. Title and Amount			9. Number of		11. Nature
	Conversion	Date (Month/Day/Year)	Execution Date, if	Transact Code				Expiration Date		of Underlying			Derivative Securities	Ownership Form of	of Indirect Beneficial
	Price of		(Month/Day/Year)			Securities Acquired (A) or Disposed of		(Monul/Day/Year)		Securities (Instr. 3 and 4)			Beneficially	Derivative	
(	Derivative		( · · · · )	<b>X</b> ,		(D)				Ň,		· /	Owned	Security:	(Instr. 4)
	Security				r	(Instr. 3, 4, and 5)							Following Reported	Direct (D) or Indirect	
								Date	Expiration		Amount		Transaction(s)		
								Exercisable		Title	or Number		(Instr. 4)	(Instr. 4)	
				Code	V	(A)	(D)				of Shares				
Stock															
option	\$ 0.24	12/08/2005		D			100,000	<u>(1)</u>	08/05/2013	Common stock	250.000	(2)	150,000	D	
(right to				_			,			stock	,			_	
buy)															
Stock										G					
option	\$ 0.8	12/08/2005		А		100,000		<u>(1)</u>	08/05/2013	Common stock	250,000	<u>(2)</u>	100,000	D	
(right to buy)										SLOCK					
Stock option										Common					
(right to	\$ 0.24	12/08/2005		D			500,000	<u>(3)</u>	01/20/2015	Common stock	500,000	<u>(4)</u>	0	D	
buy)										Stock					
Stock					-										
option										Common					
(right to	\$ 0.8	12/08/2005		А		500,000		<u>(3)</u>	01/20/2015	stock	500,000	<u>(4)</u>	500,000	D	
buy)															

## **Reporting Owners**

Denseting Operation Name (Address	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Jeong Tae Heum 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850			CFO and Secretary					

# Signatures

/s/ Tae Heum Jeong	05/03/2006	
**Signature of Reporting Person	Date	

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options vested and became exercisable as to 30% of the options on August 5, 2003; another 30% of the options on August 5, 2004; and the remaining 40% of the options on August 5, 2005.

(2) The transaction involved an amendment of outstanding options to change the exercise price with respect to 100,000 options from \$0.24 to \$0.80, resulting in the deemed cancellation of a portion of the original options and the grant of replacement options with the same vesting and exercisability terms as the cancelled options.

(3) The options vest and become exercisable as to 30% of the options on January 20, 2006; another 30% of the options on January 20, 2007; and the remaining 40% of the options on January 20, 2006;

2008.
(4) The transaction involved an amendment of outstanding options to change the exercise price with respect to 500,000 options from \$0.24 to \$0.80, resulting in the deemed cancellation of the original options and the grant of replacement options with the same vesting and exercisability terms as the cancelled options.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.